Sialylation of TLR2 initiates osteoclast fusion

Abstract

The molecular control of osteoclast formation is still not clearly elucidated. Here, we show that a process of cell recognition mediated by Siglec15-TLR2 binding is indispensable and occurs prior to cell fusion in RANKL-mediated osteoclastogenesis. Siglec15 has been shown to regulate osteoclastic bone resorption. However, the receptor for Siglec15 has not been identified, and the signaling mechanism involving Siglec15 in osteoclast function remains unclear. We found that Siglec15 bound sialylated TLR2 as its receptor and that the binding of sialylated TLR2 to Siglec15 in macrophages committed to the osteoclast-lineage initiated cell fusion for osteoclast formation, in which sialic acid was transferred by the sialyltransferase ST3Gal1. Interestingly, the expression of Siglec15 in macrophages was activated by M-CSF, whereas ST3Gal1 expression was induced by RANKL. Both Siglec15-specific deletion in macrophages and intrafemoral injection of sialidase abrogated cell recognition and reduced subsequent cell fusion for the formation of osteoclasts, resulting in increased bone formation in mice. Thus, our results reveal that cell recognition mediated by the binding of sialylated TLR2 to Siglec15 initiates cell fusion for osteoclast formation.

References

[1] Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93: 165-176

[2] Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. U.S.A., 1998, 95: 3597-3602

[3] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423: 337-342

[4] Koga T et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 2004, 428: 758-763

[5] Dai XM et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood, 2002, 99: 111-120

[6] Pettit AR et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol., 2001, 159: 1689-1699

[7] Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol., 2001, 1: 135-145

[8] Takami M, Kim N, Rho J, Choi Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J. Immunol., 2002, 169: 1516-1523

[9] Weber AN, Morse MA, Gay NJ. Four N-linked glycosylation sites in human toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. J. Biol. Chem., 2004, 279: 34589-34594

[10] Amith SR et al. Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling. Cell. Signal, 2010, 22: 314-324

[11] Varki A. Sialic acids in human health and disease. Trends Mol. Med, 2008, 14: 351-360

[12] Crean SM et al. N-linked sialyated sugar receptors support haematopoietic cell-osteoblast adhesions. Br. J. Haematol., 2004, 124: 534-546

[13] Keppler OT et al. Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology, 1999, 9: 557-569

[14] Stamatos NM, Curreli S, Zella D, Cross AS. Desialylation of glycoconjugates on the surface of monocytes activates the extracellular signal-related kinases ERK 1/2 and results in enhanced production of specific cytokines. J. Leukoc. Biol., 2004, 75: 307-313

[15] Vijay GS, Lodha SK, Sareen PM, Vijay RK. Serum sialic acid estimation in various bone disorders. J. Indian Med. Assoc., 1982, 79: 109-110

[16] Bull C et al. Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity. Cancer Res, 2018, 78: 3574-3588

[17] Urban-Wojciuk Z et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front. Immunol., 2019, 10: 2388

[18] Wang J et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med, 2019, 25: 656-666

[19] Kameda Y et al. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12. J. Bone Min. Res., 2013, 28: 2463-2475

[20] Hiruma Y et al. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice. Bone, 2013, 53: 87-93

[21] Chang L et al. Identification of siglec ligands using a proximity labeling method. J. Proteome Res, 2017, 16: 3929-3941

[22] Guccione E et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat. Cell Biol., 2006, 8: 764-770

[23] McDonald MM et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell, 2021, 184: 1330-1347 e1313

[24] Ross FP, Teitelbaum SL. alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev., 2005, 208: 88-105

[25] Stuible M et al. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J. Biol. Chem., 2014, 289: 6498-6512

[26] Hiruma Y, Hirai T, Tsuda E. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation. Biochem. Biophys. Res. Commun., 2011, 409: 424-429

[27] Briard JG, Jiang H, Moremen KW, Macauley MS, Wu P. Cell-based glycan arrays for probing glycan-glycan binding protein interactions. Nat. Commun., 2018, 9

[28] Baroukh B, Cherruau M, Dobigny C, Guez D, Saffar JL. Osteoclasts differentiate from resident precursors in an in vivo model of synchronized resorption: a temporal and spatial study in rats. Bone, 2000, 27: 627-634

[29] Ochareon P, Herring SW. Cell replication in craniofacial periosteum: appositional vs. resorptive sites. J. Anat., 2011, 218: 285-297

[30] Witten PE, Huysseune A. A comparative view on mechanisms and functions of skeletal remodelling in teleost fish, with special emphasis on osteoclasts and their function. Biol. Rev. Camb. Philos. Soc., 2009, 84: 315-346

[31] Chatani M, Takano Y, Kudo A. Osteoclasts in bone modeling, as revealed by in vivo imaging, are essential for organogenesis in fish. Dev. Biol., 2011, 360: 96-109

[32] Xie H et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med., 2014, 20: 1270-1278

[33] Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev., 2000, 21: 115-137

[34] Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Min. Res., 1996, 11: 1043-1051

[35] Krisher T, Bar-Shavit Z. Regulation of osteoclastogenesis by integrated signals from toll-like receptors. J. Cell. Biochem., 2014, 115: 2146-2154

[36] Takahata M et al. Sialylation of cell surface glycoconjugates is essential for osteoclastogenesis. Bone, 2007, 41: 77-86

[37] Chen GY et al. Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife, 2014, 3: e04066

[38] Wu Y, Ren D, Chen GY. Siglec-E negatively regulates the activation of TLR4 by controlling its endocytosis. J. Immunol., 2016, 197: 3336-3347

[39] Kawasaki N, Rademacher C, Paulson JC. CD22 regulates adaptive and innate immune responses of B cells. J. Innate Immun., 2011, 3: 411-419

[40] Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology, 2013, 23: 178-187

[41] Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl Acad. Sci. U.S.A., 2004, 101: 3029-3034

[42] Jin B, Sun T, Yu XH, Yang YX, Yeo AE. The effects of TLR activation on T-cell development and differentiation. Clin. Dev. Immunol., 2012, 2012: 836485

[43] Zanin-Zhorov A, Cohen IR. Signaling via TLR2 and TLR4 directly down-regulates T cell effector functions: the regulatory face of danger signals. Front. Immunol., 2013, 4: 211

[44] Sato K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med., 2006, 203: 2673-2682

[45] Carmona-Fernandes D, Santos MJ, Perpetuo IP, Fonseca JE, Canhao H. Soluble receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. Arthritis Res. Ther., 2011, 13: R175

[46] Li W et al. Investigation of the potential use of sialic acid as a biomarker for rheumatoid arthritis. Ann. Clin. Lab. Sci., 2019, 49: 224-231

[47] Alturfan AA et al. Increased serum sialic acid levels in primary osteoarthritis and inactive rheumatoid arthritis. Tohoku J. Exp. Med., 2007, 213: 241-248

[48] Liou LB, Huang CC. Sialyltransferase and neuraminidase levels/ratios and sialic acid levels in peripheral blood B cells correlate with measures of disease activity in patients with systemic lupus erythematosus and rheumatoid arthritis: a pilot study. PLoS ONE, 2016, 11: e0151669

[49] Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev., 2012, 31: 501-518

[50] Hernandez RK et al. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer, 2018, 18

[51] Zhang C et al. Elevated serum sialic acid levels predict prostate cancer as well as bone metastases. J. Cancer, 2019, 10: 449-457

[52] Teoh ST, Ogrodzinski MP, Ross C, Hunter KW, Lunt SY. Sialic acid metabolism: a key player in breast cancer metastasis revealed by metabolomics. Front. Oncol., 2018, 8: 174

[53] Zhu S et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J. Clin. Investig., 2019, 129: 1076-1093

[54] Ma Q et al. Osteoclast-derived apoptotic bodies couple bone resorption and formation in bone remodeling. Bone Res., 2021, 9: 5

[55] Dou C et al. Bone-targeted pH-responsive cerium nanoparticles for anabolic therapy in osteoporosis. Bioact. Mater., 2021, 6: 4697-4706

[56] Dou C et al. MiR-7b directly targets DC-STAMP causing suppression of NFATc1 and c-Fos signaling during osteoclast fusion and differentiation. Biochim. Biophys. Acta, 2014, 1839: 1084-1096

[57] Dou C et al. Graphene-based MicroRNA transfection blocks preosteoclast fusion to increase bone formation and vascularization. Adv. Sci., 2018, 5: 1700578

[58] Dou C et al. Estrogen deficiency-mediated M2 macrophage osteoclastogenesis contributes to M1/M2 ratio alteration in ovariectomized osteoporotic mice. J. Bone Min. Res, 2018, 33: 899-908

[59] Cao L et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res., 2010, 70: 6497-6508